The Relationship between female Breast Cancer and Renal Failure (Article Type: Review)
Hubungan antara Kanker Payudara Wanita dan Gagal Ginjal (Jenis Artikel: Ulasan)
-
(1) * Muntadher Mohammed Jaber
Iraqi Ministry of Health, Thi Qar Health Office
Iraq
(2) Adyan Nafea Abbas Directorate of Education Thi-Qar, Ministry of Education
Iraq
(3) Ahmed Hassan Salih Al-Bo Anah Ministry of Health / Babylon Health Department
Iraq
(4) Samer Kareem Hanoon Iraqi Ministry of Health, Thi Qar Health Office
Iraq
(5) Falah Herez Madhloom Alrabea Iraqi Ministry of Health, Thi Qar Health Office, Thi- Qar
Iraq
(*) Corresponding Author
Abstract
Following up on existing statistics and evaluating published research, we discovered that a quarter of women worldwide suffer from cancer, specifically breast cancer, which has a high fatality rate.Renal insufficiency and breast cancer etiology seem to be related in a reciprocal way. When choosing a course of treatment, this association should be taken into account. This study investigates the correlation between these two traits in patients diagnosed with breast cancer. This research paper will look into the relationship between this malignancy and kidney failure in order to determine the best treatment method. As a result, all medical and laboratory methodologies and standards must be used to determine the relationship and direct link between the two disorders. This does not indicate that there is no kidney failure owing to the lack of cancer, but due to cancer, an increase in blood calcium can occur, or due to tumor lysis syndrome (TLS), which causes renal failure in a patient who has kidney functions performing without any pathological defects. The patient's basal glomerular filtration rate should be considered by medical professionals when deciding on the optimal course of treatment for each breast cancer patient. Neglect and lack of regular monitoring of body functions, especially kidney function, through tests and monitoring of the glomerular filtration rate can increase the risk of kidney failure. When comparing cancer patients, meaning breast cancer, who suffer from kidney failure with those whose glomerular filtration rate is within the normal range, we find that the first group has high mortality rates. Therefore, these mortality rates must be reduced through scientific study and investigation to reach somewhat acceptable results. Both breast cancer and renal failure seem to share a common pathogenesis. This association should be taken into consideration while selecting a treatment approach. Physicians should consider the baseline glomerular filtration rate (GFR) of patients with breast cancer when deciding on the optimal course of therapy.
Highlights:
- Investigate breast cancer and kidney failure correlation impacting treatment approaches.
- High blood calcium or TLS may induce renal failure in patients.
- Monitor glomerular filtration rate to reduce mortality in affected patients.
Keywords: breast cancer, renal failure, tumor lysis syndrome (TLS), glomerular filtration rate (GFR).
References
D. Zouzoulas, et al., "Breast cancer in women younger than 35 years old," Archives of Gynecology and Obstetrics, vol. 302, pp. 721–730, 2020.
I. H. Kunkler, et al., "Breast-conserving surgery with or without irradiation in early breast cancer," New England Journal of Medicine, vol. 388, no. 7, pp. 585–594, 2023.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials," Lancet, vol. 365, pp. 1687–1717, May 2005, doi: 10.1016/S0140-6736(05)66544-0.
V. Sacchini and L. Norton, "Escalating de-escalation in breast cancer treatment," Breast Cancer Research and Treatment, vol. 195, pp. 85–90, 2022, doi: 10.1007/s10549-022-06685-2.
A. Howard, C. Martin, and P. Davis, "Chemotherapy and hormonal therapy overview," Core Curriculum for Oncology Nursing, pp. 257, 2023.
S. Karam, et al., "Cancer therapy in patients with reduced kidney function," Nephrology Dialysis Transplantation, 2024.
V. Launay-Vacher, N. Janus, and G. Deray, "Renal insufficiency and cancer treatments," ESMO Open, vol. 1, no. 4, 2016, doi: 10.1136/esmoopen-2015-000091.
C. W. Taylor and A. M. Kirby, "Cardiac side-effects from breast cancer radiotherapy," Clinical Oncology (Royal College of Radiologists), vol. 27, pp. 621–629, 2015, doi: 10.1016/j.clon.2015.06.007.
A. Jindeel, "Lymphedema after breast cancer treatment," New England Journal of Medicine, vol. 380, p. 694, 2019, doi: 10.1056/NEJMc1817537.
L. L. Munn, "Cancer and inflammation," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 9, no. 2, p. e1370, 2017.
F. R. Greten and S. I. Grivennikov, "Inflammation and Cancer: Triggers, Mechanisms, and Consequences," Immunity, vol. 51, no. 1, pp. 27-41, 2019.
J. Małyszko, L. Kozlowski, K. Kozłowska, M. Małyszko, and J. Małyszko, "Cancer and the Kidney: Dangereoux Liasons or Price Paid for the Progress in Medicine?," Oncotarget, vol. 8, no. 39, pp. 66601-66611, 2017.
V. B. Shahinian, A. Bahl, D. Niepel, and V. Lorusso, "Considering Renal Risk While Managing Cancer," Cancer Management and Research, pp. 167-178, 2017.
P. H. de Oliveira Filgueira, L. F. Vasconcelos, G. B. da Silva, and E. de F. Daher, "Paraneoplastic Syndromes and the Kidney," Saudi Journal of Kidney Diseases and Transplantation, vol. 21, pp. 222-231, 2010.
A. Jeyabalan and M. Trivedi, "Paraneoplastic Glomerular Diseases," Advances in Chronic Kidney Disease, vol. 29, no. 2, pp. 116-126, 2022.
G. A. Clines, "Mechanisms and Treatment of Hypercalcemia of Malignancy," Current Opinion in Endocrinology, Diabetes, and Obesity, vol. 18, pp. 339-346, 2011.
N. Asonitis, A. Angelousi, C. Zafeiris, G. I. Lambrou, I. Dontas, and E. Kassi, "Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature," Hormone and Metabolic Research, vol. 51, pp. 770-778, 2019.
K. Tanco and S. Rashid, "Hypercalcemia," in Textbook of Palliative Medicine and Supportive Care. CRC Press, 2021, pp. 563-568.
A. Jeyabalan and M. Trivedi, "Paraneoplastic Glomerular Diseases," Advances in Chronic Kidney Disease, vol. 29, pp. 116-126.e1, 2022.
A. E. Mirrakhimov, P. Voore, M. Khan, and A. M. Ali, "Tumor Lysis Syndrome: A Clinical Review," World Journal of Critical Care Medicine, vol. 4, no. 2, pp. 130-138, 2015.
A. K. Abu-Alfa and A. Younes, "Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management," American Journal of Kidney Diseases, vol. 55, pp. S1-S13, 2010.
M. Abdel-Nabey et al., "Tumor Lysis Syndrome, Acute Kidney Injury and Disease-Free Survival in Critically Ill Patients Requiring Urgent Chemotherapy," Annals of Intensive Care, vol. 12, p. 15, 2022.
C. F. Almeida et al., "Estrogen Receptor-Positive (ER+) Breast Cancer Treatment: Are Multi-Target Compounds the Next Promising Approach?," Biochemical Pharmacology, vol. 177, p. 113989, 2020.
N. Pellicer, D. Galliano, and A. Pellicer, "Ovarian Hyperstimulation Syndrome," in The Ovary. Academic Press, 2019, pp. 345-362.
R. Abou Arkoub, C. W. Xiao, P. Claman, and E. G. Clark, "Acute Kidney Injury Due to Ovarian Hyperstimulation Syndrome," American Journal of Kidney Diseases, vol. 73, pp. 416-420, 2019.
M. E. Kalender et al., "Anastrozole-Associated Sclerosing Glomerulonephritis in a Patient with Breast Cancer," Oncology, vol. 73, pp. 415-418, 2007.
S. Yoshimoto et al., "A Case of Crescentic Glomerulonephritis Developed Under Oral Anastrozole Treatment," Gan To Kagaku Ryoho, vol. 40, pp. 267-270, 2013.
M. Conti-Beltraminelli et al., "Henoch-Schönlein Purpura (HSP) During Treatment with Anastrozole," Annals of Oncology, vol. 18, pp. 205-207, 2007.
R. A. Wermers and E. G. Abate, "Medication-Induced Hypercalcemia," in Hypercalcemia: Clinical Diagnosis and Management. Springer, 2022, pp. 209-222.
R. Yu, "Hypercalcemic Crisis Associated with Anastrozole Use in a Patient with Breast Cancer and Primary Hyperparathyroidism," Endocrine, vol. 53, pp. 868-869, 2016.
S. H. Ipekci, S. Baldane, E. Ozturk, M. Araz, H. Korkmaz, F. Colkesen, et al., "Letrozole-Induced Hypercalcemia in a Patient with Breast Cancer," Case Reports in Oncology Medicine, vol. 2014, p. 608585, 2014, doi: 10.1155/2014/608585.
R. N. Almutlaq, A. E. Newell-Fugate, L. C. Evans, H. Fatima, and E. Y. Gohar, "Aromatase Inhibition Increases Blood Pressure and Markers of Renal Injury in Female Rats," American Journal of Physiology: Renal Physiology, vol. 323, pp. F349-F360, 2022, doi: 10.1152/ajprenal.00055.2022.
R. F. Swaby, C. G. Sharma, and V. C. Jordan, "SERMs for the Treatment and Prevention of Breast Cancer," Reviews in Endocrine and Metabolic Disorders, vol. 8, pp. 229-239, 2007, doi: 10.1007/s11154-007-9034-4.
L. Van Dyk, "Combinatorial Treatments of Tamoxifen with SM6Met, a Selective Estrogen Receptor Subtype Modulator (SERSM), from Cyclopia subternata Are Superior to Current Endocrine Treatments in Breast Cancer Cell Models," Dissertation, Stellenbosch University, Stellenbosch, 2018.
M. Saito and K. Marumo, "Calcium and Bone Metabolism Across Women’s Life Stages: Bone Quality and Treatment of Osteoporosis by SERM," Clinical Calcium, vol. 27, pp. 723-732, 2017.
K. Nitta, A. Yajima, and K. Tsuchiya, "Management of Osteoporosis in Chronic Kidney Disease," Internal Medicine, vol. 56, pp. 3271-3276, Dec. 2017, doi: 10.2169/internalmedicine.8618-16.
N. Moradi, S. Izadi, and H. R. Hemmati, "Renal Insufficiency in Breast Cancer Patients: A Review Study," Journal of Nephropharmacology, vol. 13, no. 2, p. e11659, 2024.
M. M. Ilg, "Investigating the Effect of Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators in Models of Peyronie's Disease," Dissertation, Anglia Ruskin Research Online (ARRO), 2023.
N. Sharma, "Involvement of Histone H3 Methylation, Angiotensin-Converting Enzyme 2, and Angiotensin II Type 2 Receptor in the Pathogenesis of Acute Kidney Injury under Type 1 Diabetic and Non-Diabetic Conditions," Dissertation, BITS Pilani, 2020.
F. Poggio, M. Tagliamento, M. Ceppi, M. Bruzzone, B. Conte, P. Fregatti, et al., "Adding a Platinum Agent to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: The End of the Debate," Annals of Oncology, vol. 33, pp. 347-349, 2022, doi: 10.1016/j.annonc.2021.11.016.
N. Pabla and Z. Dong, "Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies," Kidney International, vol. 73, pp. 994-1007, 2008, doi: 10.1038/sj.ki.5002786.
H. M. Coley, "Mechanisms and Strategies to Overcome Chemotherapy Resistance in Metastatic Breast Cancer," Cancer Treatment Reviews, vol. 34, pp. 378-390, 2008, doi: 10.1016/j.ctrv.2008.01.007.
M. Singh, N. Kumar, M. Shuaib, V. K. Garg, and A. Sharma, "A Review on Renal Protective Agents for Cyclophosphamide-Induced Nephrotoxicity," World Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, pp. 737-747, 2014.
M. A. Ayza, K. A. Zewdie, E. F. Yigzaw, S. G. Ayele, B. A. Tesfaye, G. G. Tafere, et al., "Potential Protective Effects of Antioxidants Against Cyclophosphamide-Induced Nephrotoxicity," International Journal of Nephrology, vol. 2022, p. 5096825, 2022, doi: 10.1155/2022/5096825.
M. Mahfouz, "Determination of Drug-Drug Interaction in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Regimen in North Cyprus," Dissertation, Near East University, 2022.
E. G. Mimnaugh, M. A. Trush, and T. E. Gram, "A Possible Role for Membrane Lipid Peroxidation in Anthracycline Nephrotoxicity," Biochemical Pharmacology, vol. 35, pp. 4327-4335, 1986, doi: 10.1016/0006-2952(86)90713-6.
T. S. Lahoti, D. Patel, V. Thekkemadom, R. Beckett, and S. D. Ray, "Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress-Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways," Current Neurovascular Research, vol. 9, pp. 282-295, 2012, doi: 10.2174/156720212803530636.
R. J. B. Jorge, et al., "Antioxidants and Kidney Diseases," in Antioxidants Effects in Health. Elsevier, 2022, pp. 755-798.
J. Ren, Z. Huo, X. Wang, Y. Liu, and G. Yang, "Serial Renography for Evaluation of the Impact of Capecitabine Therapy on Renal Function: A Case Report," Medicine (Baltimore), vol. 96, p. e6861, 2017, doi: 10.1097/MD.0000000000006861.
S. E. Mikhail, J. F. Sun, and J. L. Marshall, "Safety of Capecitabine: A Review," Expert Opinion on Drug Safety, vol. 9, pp. 831-841, 2010, doi: 10.1517/14740338.2010.511610.
[51] I. Glezerman, M. G. Kris, V. Miller, S. Seshan, and C. D. Flombaum, "Gemcitabine Nephrotoxicity and Hemolytic Uremic Syndrome: Report of 29 Cases from a Single Institution," Clin. Nephrol., vol. 71, pp. 130-139, 2009, doi: 10.5414/cnp71130.
H. Fukasawa, R. Furuya, H. Yasuda, T. Yamamoto, A. Hishida, and M. Kitagawa, "Anti-Cancer Agent-Induced Nephrotoxicity," Anticancer Agents Med. Chem., vol. 14, pp. 921-927, 2014, doi: 10.2174.
H. Izzedine, C. Isnard-Bagnis, V. Launay-Vacher, L. Mercadal, I. Tostivint, O. Rixe, et al., "Gemcitabine-Induced Thrombotic Microangiopathy: A Systematic Review," Nephrol. Dial. Transplant., vol. 21, pp. 3038-3045, 2006, doi: 10.1093/ndt/gfl507.
V. Yang, M. J. Gouveia, J. Santos, B. Koksch, I. Amorim, F. Gärtner, et al., "Breast Cancer: Insights in Disease and Influence of Drug Methotrexate," RSC Med. Chem., vol. 11, pp. 646-664, 2020, doi: 10.1039/d0md00051e.
T. Wiczer, E. Dotson, A. Tuten, G. Phillips, and K. Maddocks, "Evaluation of Incidence and Risk Factors for High-Dose Methotrexate-Induced Nephrotoxicity," J. Oncol. Pharm. Pract., vol. 22, pp. 430-436, 2016, doi: 10.1177/1078155215594417.
B. C. Widemann and P. C. Adamson, "Understanding and Managing Methotrexate Nephrotoxicity," Oncologist, vol. 11, pp. 694-703, 2006, doi: 10.1634/theoncologist.11-6-694.
Y. C. Xu, H. X. Wang, L. Tang, Y. Ma, and F. C. Zhang, "A Systematic Review of Vinorelbine for the Treatment of Breast Cancer," Breast J., vol. 19, pp. 180-188, 2013, doi: 10.1111/tbj.12071.
M. Aapro and J. Finek, "Oral Vinorelbine in Metastatic Breast Cancer: A Review of Current Clinical Trial Results," Cancer Treat. Rev., vol. 38, pp. 120-126, 2012, doi: 10.1016/j.ctrv.2011.05.005.
F. Zeng, R. J. Ju, L. Liu, H. J. Xie, L. M. Mu, and W. L. Lu, "Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes," Pharmacology, vol. 101, pp. 43-53, 2018, doi: 10.1159/000480737.
M. C. Fung, A. M. Storniolo, B. Nguyen, M. Arning, W. Brookfield, and J. Vigil, "A Review of Hemolytic Uremic Syndrome in Patients Treated with Gemcitabine Therapy," Cancer, vol. 85, no. 9, pp. 2023-2032, 1999.
H. Kanchi, N. J. Webb, and O. B. Eden, "Hemolytic Uremic Syndrome Secondary to the Treatment of Acute Lymphoblastic Leukemia," J. Pediatr. Hematol. Oncol., vol. 22, pp. 483-484, 2000, doi: 10.1097/00043426-200009000-00024.
F. S. Farhat, S. Temraz, J. Kattan, K. Ibrahim, N. Bitar, N. Haddad, et al., "A Phase II Study of Lipoplatin (Liposomal Cisplatin)/Vinorelbine Combination in HER-2/Neu-Negative Metastatic Breast Cancer," Clin. Breast Cancer, vol. 11, pp. 384-389, 2011, doi: 10.1016/j.clbc.2011.08.005.
F. Farhat, K. Ibrahim, J. Kattan, N. Bitar, R. Jalloul, G. Nsouly, et al., "Preliminary Results of a Phase II Study of Liposomal Cisplatin-Vinorelbine Combination as First-Line Treatment in HER2/Neu-Negative Metastatic Breast Cancer (MBC)," J. Clin. Oncol., vol. 27, p. 1068, 2009.
J. Crown, M. O’Leary, and W. S. Ooi, "Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience," Oncologist, vol. 9, suppl. 2, pp. 24-32, 2004, doi: 10.1634/theoncologist.9-suppl_2-24.
C. Gur, F. M. Kandemir, C. Caglayan, and E. Satici, "Chemopreventive Effects of Hesperidin Against Paclitaxel-Induced Hepatotoxicity and Nephrotoxicity via Amendment of Nrf2/HO-1 and Caspase-3/Bax/Bcl-2 Signaling Pathways," Chem. Biol. Interact., vol. 365, p. 110073, 2022, doi: 10.1016/j.cbi.2022.110073.
J. Mohri, C. Katada, M. Ueda, M. Sugawara, K. Yamashita, H. Moriya, et al., "Predisposing Factors for Chemotherapy-Induced Nephrotoxicity in Patients with Advanced Esophageal Cancer Who Received Combination Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil," J. Transl. Int. Med., vol. 6, pp. 32-37, 2018, doi: 10.2478/jtim-2018-0007.
D. You, et al., "Increase in Serum Creatinine Levels After PARP Inhibitor Treatment," J. Obstet. Gynaecol., vol. 43, no. 1, 2023, doi: 10.1080/01443615.2023.2171781.
E. Bas and M. Naziroglu, "Selenium Attenuates Docetaxel-Induced Apoptosis and Mitochondrial Oxidative Stress in Kidney Cells," Anticancer Drugs, vol. 30, pp. 339-346, 2019, doi: 10.1097/CAD.0000000000000723.
M. A. C. Bruin, C. M. Korse, B. van Wijnen, V. M. T. de Jong, S. C. Linn, B. van Triest, et al., "A Real or Apparent Decrease in Glomerular Filtration Rate in Patients Using Olaparib?," Eur. J. Clin. Pharmacol., vol. 77, pp. 179-188, 2021, doi: 10.1007/s00228-020-03070-0.
A. H. Paterson, "Bisphosphonates: Biological Response Modifiers in Breast Cancer," Clin. Breast Cancer, vol. 3, pp. 206-216, 2002, doi: 10.3816/CBC.2002.n.025.
P. Gudsoorkar, A. Langote, P. Vaidya, and A. Y. Meraz-Muñoz, "Acute Kidney Injury in Patients with Cancer: A Review of Onconephrology," Adv. Chronic Kidney Dis., vol. 28, no. 5, pp. 394-401, 2021.
D. W. Luedders, J. Steinhoff, M. Thill, A. Rody, and M. K. Bohlmann, "Lack of Difference in Acute Nephrotoxicity of Intravenous Bisphosphonates Zoledronic Acid and Ibandronate in Women with Breast Cancer and Bone Metastases," Anticancer Res., vol. 35, pp. 1797-1802, 2015.
E. J. Watkins, "Overview of Breast Cancer," JAAPA, vol. 32, pp. 13-17, 2019, doi: 10.1097/01.JAA.0000580524.95733.3d.
A.-S. Garnier, H. Laubacher, and M. Briet, "Drug-Induced Glomerular Diseases," Therapies, 2023.
J. E. Moulder, et al., "Angiotensin Converting Enzyme (ACE) Inhibitors as Radiation Countermeasures for Long-Duration Space Flights," Life Sci. Space Res., vol. 35, pp. 60-68, 2022.
J. Yang, et al., "The Role of the Renin-Angiotensin System Inhibitors in Malignancy: A Review," Am. J. Cancer Res., vol. 11, no. 3, pp. 884, 2021.
L. Cosmai, et al., "Preventive Strategies for Acute Kidney Injury in Cancer Patients," Clin. Kidney J., vol. 14, no. 1, pp. 70-83, 2021.
T. Ebert, et al., "Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients," Antioxidants Redox Signal., vol. 35, no. 17, pp. 1426-1448, 2021.
K. Wang and J. E. Tepper, "Radiation Therapy-Associated Toxicity: Etiology, Management, and Prevention," CA Cancer J. Clin., vol. 71, pp. 437-454, 2021, doi: 10.3322/caac.21689.
A. S. Parihar, S. Chopra, and V. Prasad, "Nephrotoxicity After Radionuclide Therapies," Transl. Oncol., vol. 15, p. 101295, 2022, doi: 10.1016/j.tranon.2021.101295.
M. Hu, Q. Wang, B. Liu, Q. Ma, T. Zhang, T. Huang, et al., "Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms," Frontiers in Cell and Developmental Biology, vol. 10, p. 868715, 2022, doi: 10.3389/fcell.2022.868715.
B. Stengel, "Chronic Kidney Disease and Cancer: A Troubling Connection," Journal of Nephrology, vol. 23, pp. 253-262, 2010.
A. Atris, I. Al Salmi, F. Al Rahbi, B. J. Al-Bahrani, and S. Hannawi, "Epidemiology of Cancer Among Chronic Kidney Disease Patients Compared to The General Population," Gulf Journal of Oncology, vol. 1, pp. 7-15, 2022.
M. H. Rosner, "Cancer Screening in Patients Undergoing Maintenance Dialysis: Who, What, and When," American Journal of Kidney Diseases, vol. 76, no. 4, pp. 558-566, 2020.
T. Nyman, et al., "Inflammatory Markers and Coagulation in Cancer: Mechanisms and Implications for Therapy," Journal of Clinical Oncology, vol. 32, no. 30, pp. 3273-3283, 2014.
S. C. Palmer, et al., "Dietary and Fluid Restrictions in CKD: A Thematic Synthesis of Patient Views From Qualitative Studies," American Journal of Kidney Diseases, vol. 65, no. 4, pp. 559-573, 2015.
